Mucinous ovarian carcinoma (MOC) represents a rare and biologically distinct subtype of ovarian cancer, characterized by poor response to standard platinum-based chemotherapy and a unique molecular profile, including frequent KRAS mutations and HER2 amplifications. Recent advancements in targeted therapy, such as HER2 inhibitors and KRASG12C inhibitors, offer promising avenues for personalized treatment. Immunotherapy, particularly checkpoint inhibitors, shows potential in tumors with high PD-L1 expression or tumor mutational burden. Novel strategies, including antibody–drug conjugates, synthetic lethality approaches, and Wnt/β-catenin pathway inhibitors, are reshaping the therapeutic landscape. Despite these developments, challenges such as intratumoral heterogeneity and therapy resistance persist, underscoring the need for innovative clinical trial designs and combination regimens. This review synthesizes the latest advancements in MOC therapies, highlighting opportunities for improved outcomes in this challenging malignancy.
30 June 2026 in International Journal of Innovative Technologies in Social Science
Migraine is a highly prevalent neurological disease associated with considerable personal, social, and economic burden. The disease represents a major contributor to disability and reduced quality of life. Over the years migraine pharmacotherapy has evolved from non-specific vasoconstrictive agents such as ergot alkaloids to mechanism-based therapies targeting serotonin and CGRP pathways, including triptans, gepants, ditans, and monoclonal antibodies. This review analyzes modern treatment approaches on migraine and evaluates their clinical relevance.
15 June 2026 in International Journal of Innovative Technologies in Social Science
Irritable bowel syndrome (IBS) is a common disorder of gut/brain interaction characterised by abdominal pain and altered bowel habits with a substantial burden on quality of life. Increasing evidence implicates disrupted gut barrier function, low‑grade mucosal inflammation and microbiota shifts as key pathophysiological mechanisms. Dietary polyphenols possess anti inflammatory, antioxidant and prebiotic activity. A growing number of randomised controlled trials demonstrate that polyphenol based nutraceuticals improve IBS symptoms and quality of life. Similarly, increasing physical activity appears to reduce global IBS symptoms, even though the certainty of the evidence is very low. However, mechanistic validation remains limited. Most trials prioritise patient reported outcomes over integrated multi domain biomarker phenotyping and no IBS study has directly tested whether combined polyphenol and physical activity interventions produce synergistic effects. This review integrates evidence on polyphenols and physical activity in IBS, focusing on gut barrier function, inflammation and microbiota modulation. The findings show that inflammatory modulation (CRP, IL‑6, TNF‑α, GM‑CSF) is the most consistently supported mechanistic domain, while barrier proxies (zonulin, I‑FABP) often remain unchanged despite clinical benefit. Convergent pathways from mechanistic exercise studies and animal models suggest biological plausibility for synergy, but evidence based testing in IBS is lacking. To determine whether combining lifestyle strategies produces synergistic, clinically meaningful benefits in IBS, future factorial trials must include interaction testing. They should also integrate coordinated measurements of clinical, barrier, inflammatory and microbiome endpoints.
18 June 2026 in International Journal of Innovative Technologies in Social Science
Dementia is a significant public health concern that is expected to worsen in the future due to the growing proportion of elderly people in the population. One of the important and modifiable risk factors for this condition is alcohol consumption. The effect of alcohol on the development of dementia is dose-dependent; excessive intake increases the overall risk of developing dementia and also leads to a characteristic alcohol-induced neurocognitive disorder, sometimes referred to as alcohol-related dementia. Even moderate alcohol intake results in detectable changes in the brain, observable from a young age. These effects are caused by alcohol-induced neurotoxicity, including mechanisms such as neuroinflammation, the production of reactive oxygen species (ROS), acetaldehyde toxicity, and thiamine deficiency. This review summarizes the impact of alcohol consumption on the development of dementia, as well as the mechanisms of neurotoxicity caused by ethanol and its metabolic products. Methodology: The study was based on scientific articles available in the PubMed and Google Scholar databases.
27 June 2026 in International Journal of Innovative Technologies in Social Science
Introduction and objective: The prostate is a single glandular organ found only in men. Anatomically it is located below the urinary bladder, with the prostatic urethra passing through it. The function of the gland is to secrete fluid, which forms up to 30% of the semen. Physiologically, the dimensions of the organ are approximately 3 cm x 4 cm x 2.5 cm and the weight is 20-25 g. Due to its location, prostate enlargement can lead to constriction of the urethra, which in turn can lead to disturbances in micturition and sexual function. Benign prostatic hyperplasia (BPH) is a common condition affecting men, whose prevalence increases with age. It often leads to lower urinary tract symptoms (LUST) - a group of urinary issues affecting storage (frequency, urgency, incontinence) and voiding (weak stream, hesitancy, straining). For many years, transurethral resection of the prostate (TURP) has remained the gold standard for BPH treatment. However, it is not the only available treatment method. Transurethral incision of the prostate gland (TUIP) is a less invasive method dedicated for less advanced prostatic hyperplasia. This study aims to compare the efficacy and safety of TURP and TUIP based on literature review and comparison of scientific research. Materials and methodology: The article was written based on a thorough analysis of scientific papers available on PubMed and Google Scholar, which serve as verified sources of information.
24 June 2026 in International Journal of Innovative Technologies in Social Science
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, or gliflozins, represent one of the most significant pharmacological breakthroughs in modern cardiovascular and renal medicine. Originally developed as glucose-lowering agents for type 2 diabetes, these medications have demonstrated profound, life-saving cardiovascular benefits in patients, regardless of their glycemic status. This shift from a "glucocentric" to an "organoprotective" paradigm is driven by a complex array of pleiotropic mechanisms that transcend simple osmotic diuresis. This work provides a comprehensive analysis of the multifaceted physiological pathways through which SGLT2 inhibitors exert their effects. Key mechanisms explored include the optimization of myocardial bioenergetics through ketone body utilization, the stabilization of ion exchange, the restoration of tubuloglomerular feedback, reduction of epicardial adipose tissue, microbiome management and improvement in cardiac muscle remodelling. This review evaluates the landmark clinical evidence from pivotal trials such as EMPA-REG, DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DELIVER, DAPA-MODA, DAPA-CKD, CREDENCE, EMPA-KIDNEY, DAPA-MI and EMPACT-MI; exploring the SGLT2i role in patients with heart failure and chronic kidney disease. These studies have established SGLT2 inhibitors as the first class of therapy to show consistent mortality and morbidity benefits across the entire spectrum of left ventricular ejection fraction. The work also addresses recent 2024 to 2025 data regarding early implementation in the post-myocardial infarction setting and the emerging role of the gut-kidney-heart axis in modulating systemic inflammation. Materials and Methods: The article was written based on scientific papers available on PubMed and Google Scholar.